Inhibikase Therapeutics Inc（IKT）资讯与事件IKTInhibikase Therapeutics Inc

Inhibikase Therapeutics Appoints Scott Wasserman to Board

Inhibikase Therapeutics (IKT) announced the appointment of Scott Wasserman to the company's board of directors, effective immediately. Concurrent with Wasserman's appointment, the company also announced the resignation of Dennis Berman from the company's board. Wasserman is currently the chief medical officer, or CMO, of Kailera Therapeutics (KLRA).

Inhibikase Advances IKT-001 Clinical Study and Receives FDA Orphan Drug Designation

"During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries," said Mark Iwicki, Chief Executive Officer of Inhibikase. "Also, during the quarter, favorable results of pre-clinical and Phase 1 studies of IKT-001 were presented at the American Thoracic Society International Conference, with data demonstrating improvements in pulmonary vascular and hemodynamic markers of PAH and lower potential for GI toxicity compared to imatinib mesylate. Together with the recent grant of Orphan Drug Designation from the U.S. FDA and the $50 million proceeds from the sale of shares to RA Capital, Inhibikase is well-positioned to advance IKT-001 toward its potential as the first once-daily oral anti-proliferative offering significant potential benefits to the PAH patient population."

Inhibikase Therapeutics Receives Orphan Drug Designation for IKT-001

Inhibikase Therapeutics announced that the FDA has granted Orphan Drug Designation to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH.